ALGOTX
14.3.2023 08:02:19 CET | Business Wire | Press release
European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”
Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.
Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”
Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.
About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.
ABOUT TURENNE GROUP/RELYENS INNOVATION SANTÉ
Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: www.relyens.eu/fr / www.turennecapital.com
About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: www.bpifrance.com – Follow us on Twitter : @bpifrance - @BpifrancePresse
About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Expands DACH Presence With Xsolla Connect Berlin and Sponsorship of Games Ground Berlin4.11.2026 11:00:00 CET | Press release
Coordinated Activations Across Berlin Underscore Xsolla’s Continued Investment In The DACH Games Ecosystem, Bringing Developers, Publishers, Creators, And Partners Together Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announces a comprehensive program of activations across Berlin throughout November 2026. As a main partner of Games Ground Berlin, Xsolla is supporting the festival’s Publisher Connect program and is hosting Xsolla Connect Berlin: Publisher & Content Creator Edition, bringing together developers, publishers, and creators to explore new opportunities for collaboration and growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103176221/en/ Graphic: Xsolla During Games Ground Berlin, Xsolla will host Xsolla Connect Berlin, bringing together 15 publishers and over 40 selected German content creators at Alte Münze on November 6 for curated netwo
Yamaha Motor to Exhibit All-New RW Series’ RW700 and RW350 at EICMA4.11.2026 10:00:00 CET | Press release
- Adventure Scooters Bringing New Enjoyment to Mobility - Yamaha Motor Co., Ltd. (TOKYO: 7272) announced today that it will exhibit its new RW700 and RW350 models at EICMA 2026 (International Two-Wheeler Exhibition), one of Europe's largest motorcycle shows, to be held in Milan, Italy, from November 3rd. “RW” is an all-new series of models for global markets developed as new adventure scooters to transform everyday mobility into an experience bringing more color to people's lifestyles. The RW Series aims to offer new mobility experiences that seamlessly connect everyday life with the extraordinary, opening up new possibilities and discoveries in people’s lives by letting them explore detours off familiar roads that lead them to new sights and Kando. In addition to providing comfort and ease of use for urban environments, the RW Series boasts features and performance that entice users to freely turn off familiar roads and head out toward new scenery and experiences. The styling features
ANS Cuts IT Alert Noise by 83% with LogicMonitor Edwin AI4.11.2026 09:30:00 CET | Press release
Early results also show 45% fewer observability cases and 44% faster incident resolution, giving ANS engineers more time to improve customer services LogicMonitor®, the AI-first platform for Autonomous IT, and ANS Group, a leading UK technology and managed services provider, today announced early results from ANS's deployment of Edwin AI, demonstrating how AI is helping reshape managed services by reducing routine operational work and creating more capacity for proactive customer value. Since deploying Edwin AI in August 2026, ANS has reduced alert noise by 83%, observability incident volumes by 45% and average incident resolution times by 44%, while reporting a 500% return on its incremental Edwin AI investment.* ANS has also consistently maintained SLA performance above 97%. By correlating related alerts, accelerating investigations and recommending next steps, Edwin AI is helping ANS shift engineering capacity from reactive incident management toward more proactive customer services
LogicMonitor Makes AI the Standard, Not the Upgrade4.11.2026 09:00:00 CET | Press release
New platform packages include Edwin AI and Digital Experience at every tier, uniting signals, context and governed action on one licensing model LogicMonitor®, the AI-first platform for Autonomous IT, today announced new platform packages that make Edwin AI and LogicMonitor Digital Experience, including Synthetics and Internet Sonar, standard in every tier. By bringing full digital experience and internet health visibility together with AI-driven operations in every package, LogicMonitor helps teams connect what users experience to the signals behind it and move toward a governed next step. AI is now essential to modern IT operations, yet too often, the capabilities needed to put it into practice remain fragmented across tools and licensing models. As enterprises move toward Autonomous IT, access to AI-driven intelligence and end-to-end visibility must become the foundation, not an added layer of complexity. “IT teams don't need more separate Observability tools with AI bolted on; they
AiDEN Auto and Volvo Trucks First to Offer Embedded E-Transportation Regulatory Compliance Through the Infotainment System4.11.2026 09:00:00 CET | Press release
An industry-first integration brings RO e-Trans compliance monitoring directly into the Volvo Trucks infotainment interface and Volvo Connect, making regulatory management easier, safer, and more efficient for drivers and fleets. AiDEN Auto, a pioneer in connected vehicle software solutions, has partnered with Volvo Trucks to integrate RO e-Trans regulatory compliance management directly into the truck's in-cab infotainment system and the Volvo Connect back-office portal. Made available through Volvo Trucks' suite of digital services and Volvo Connect ecosystem, this innovative application allows drivers and fleet managers to monitor and maintain compliance with Romania's mandatory national e-Transport regulations in real time—without leaving the cab or relying on secondary mobile devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104342472/en/ AiDEN Auto, a pioneer in connected vehicle software solutions, has partne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom